Your browser doesn't support javascript.
loading
Angiotensin II Receptor Blocker Associated With Less Outcome Risk in Patients With Acute Kidney Disease.
Wu, Vin-Cent; Lin, Yu-Feng; Teng, Nai-Chi; Yang, Shao-Yu; Chou, Nai-Kuan; Tsao, Chun-Hao; Chen, Yung-Ming; Chueh, Jeff S; Chen, Likwang.
Afiliação
  • Wu VC; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Lin YF; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Teng NC; Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan.
  • Yang SY; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Chou NK; Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
  • Tsao CH; Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
  • Chen YM; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Chueh JS; Glickman Urological and Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, United States.
  • Chen L; Department of Urology, National Taiwan University Hospital, Taipei, Taiwan.
Front Pharmacol ; 13: 714658, 2022.
Article em En | MEDLINE | ID: mdl-35517809
ABSTRACT

Objective:

The aim of this study was to explore the respective use of angiotensin-converting-enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) on the outcomes of patients who could be weaned from dialysis-requiring acute kidney injury (AKI-D).

Methods:

This case-control study enrolled 41,731 patients who were weaned from AKI-D for at least 7 days from Taiwan's National Health Insurance Administration. We further grouped AKI-D patients according to ACEi and ARB use to evaluate subsequent risks of all-cause mortality and re-dialysis. The outcomes included the all-cause mortality and new-onset of end-stage kidney disease (ESKD; re-dialysis) following withdraw from AKI-D.

Results:

A total of 17,141 (41.1%) patients surviving AKI-D could be weaned from dialysis for at least 7 days. The overall events of mortality were 366 (48.9%) in ACEi users, 659 (52.1%) in ARB users, and 6,261 (41.3%) in ACEi/ARB nonusers, during a mean follow-up period of 1.01 years after weaning from AKI-D. In regard to all-cause of mortality, pre-dialysis ARB users had lower incidence than ACEi users [hazard ratio (HR 0.82), p = 0.017]. Compared with ACEi/ARB nonusers, continuing ARB users had a significantly low risk of long-term all-cause mortality (adjusted hazard ratio 0.51, p = 0.013) after propensity score matching. However, new users of ACEi at the acute kidney disease (AKD) period had a higher risk of re-dialysis after weaning than ACEi/ARB nonusers (aHR 1.82, p < 0.001), whereas neither ACEi nor ARB users confronted significantly increased risks of hyperkalemia after weaning.

Conclusions:

Compared with patients without ACEi/ARB, those continuing to use ARB before the event and after weaning had low all-cause mortality, while new users of ACEi at AKD had increased risk of re-dialysis. AKI-D patients continuing to use ACEi or ARB did not have higher risk of hyperkalemia. Future prospective randomized trials are expected to confirm these findings.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2022 Tipo de documento: Article